



FOR IMMEDIATE RELEASE

**Contact:** Andy Lee - Vincere Biosciences  
**Phone:** 857-245-9492  
**Email:** info@VincereBio.com

## **Vincere Biosciences Inc launched to win the fight against Parkinson's disease**

Cambridge, MA, USA - October 2018: [Vincere Biosciences, Inc.](#), a Delaware corporation headquartered in Cambridge, MA was created to commercialize a series of therapeutic assets thought to increase mitophagy, a biological process linked to Parkinson's and Alzheimer's diseases as well as aging. The company was spun out from [NeuroInitiative, LLC](#) a computational biology company focused on identifying drug targets for Parkinson's disease and seeded with intellectual property and funding from NeuroInitiative along with a small cohort of angel investors. CEO Dr. Spring (Bahareh) Behrouz, PhD who has dedicated over 15 years of Parkinson's disease research experience says **"With the help of like-minded investors, we are excited to move our Parkinson's drug discovery work forward with the goal of bringing relief to millions of patients."**

Vincere is pursuing small molecule modulators of multiple enzymes which aim to slow the progression of Parkinson's disease by using the cell's own repair pathways (mitophagy) to clear damaged mitochondria (powerhouses of the cell). Laboratory and computational models strongly suggest repairing mitochondrial health by modulation of these biological targets may slow or stop the progression of Parkinson's disease and other age related disorders.

To develop these compounds, Vincere has recruited Chief Scientific Officer Dr. Kalpana Merchant, PhD who brings over 25 years of drug discovery expertise, previously as CSO of tailored neuroscience therapeutics at Eli Lilly. Investor and Board director Jim Liang commented, **"We are thrilled to have Dr. Merchant leading the drug discovery efforts at Vincere. Her extensive expertise and experience will help the team avoid pitfalls and ensure rigorous validation as the team develops the pipeline."**

Rounding out the management team is Andy Lee who brings over 20 years leading large-scale projects and teams, and is the architect of NeuroInitiative's computational drug discovery platform. **"The pace of new discoveries from the scientific world is blistering and new**

**technologies allow us to identify the signal of truth from the noise to test hypotheses much faster while minimizing negative data in the lab.”** Vincere’s pipeline approach reduces risk by providing multiple shots-on-goal as well as synergistic cost savings through reuse of assays across programs. With a blend of innovation and expertise Vincere is well positioned to execute on an aggressive discovery and development effort to bring to clinic therapeutics for challenging diseases with complex biology.

**About Vincere Biosciences Inc:** Vincere Biosciences was founded in 2018 and develops therapeutics for neurodegenerative disease empowered by a unique suite of computational tools coupled with traditional biology and drug discovery expertise. Vincere is Latin for “To win” a constant reminder of our mission to win the fight against disease. <http://www.vincerebio.com>

**About NeuroInitiative LLC:** NeuroInitiative LLC was founded in 2014 to develop new computational tools that blend the latest innovation and science to understand the biology of disease. The patented SEED simulation platform along with proprietary datasets and machine learning algorithms enable NeuroInitiative to rapidly identify and validate targets for complex biology. <https://www.neuroinitiative.com>